WO2022177029A1 - セレノネインを含む、covid19治療又は予防薬 - Google Patents
セレノネインを含む、covid19治療又は予防薬 Download PDFInfo
- Publication number
- WO2022177029A1 WO2022177029A1 PCT/JP2022/007397 JP2022007397W WO2022177029A1 WO 2022177029 A1 WO2022177029 A1 WO 2022177029A1 JP 2022007397 W JP2022007397 W JP 2022007397W WO 2022177029 A1 WO2022177029 A1 WO 2022177029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- selenoneine
- protease
- papain
- coronavirus
- pro
- Prior art date
Links
- MTIQLELFQVCRSW-ZETCQYMHSA-N selenoneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=[Se])N1 MTIQLELFQVCRSW-ZETCQYMHSA-N 0.000 title claims abstract description 61
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title claims description 10
- 230000000069 prophylactic effect Effects 0.000 title claims description 6
- 239000004365 Protease Substances 0.000 claims abstract description 37
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 108091005804 Peptidases Proteins 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 3
- 101800000535 3C-like proteinase Proteins 0.000 claims description 26
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 claims description 26
- 101800004803 Papain-like protease Proteins 0.000 claims description 25
- 108090000526 Papain Proteins 0.000 claims description 20
- 229940055729 papain Drugs 0.000 claims description 20
- 235000019834 papain Nutrition 0.000 claims description 20
- 241000711573 Coronaviridae Species 0.000 claims description 18
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 17
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 15
- 239000000539 dimer Substances 0.000 claims description 13
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 10
- 235000019419 proteases Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 3
- 241001678559 COVID-19 virus Species 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 24
- 229950010033 ebselen Drugs 0.000 description 24
- 235000013305 food Nutrition 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 19
- 102000035195 Peptidases Human genes 0.000 description 15
- 235000019688 fish Nutrition 0.000 description 15
- 241000251468 Actinopterygii Species 0.000 description 14
- 230000003197 catalytic effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108010005843 Cysteine Proteases Proteins 0.000 description 10
- 102000005927 Cysteine Proteases Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 235000014304 histidine Nutrition 0.000 description 9
- JULROCUWKLNBSN-UHFFFAOYSA-N selenocystine Chemical compound OC(=O)C(N)C[Se][Se]CC(N)C(O)=O JULROCUWKLNBSN-UHFFFAOYSA-N 0.000 description 9
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- 241000269838 Thunnus thynnus Species 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 229940093497 ergothioneine Drugs 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108010076039 Polyproteins Proteins 0.000 description 6
- XDSSPSLGNGIIHP-VKHMYHEASA-N Se-methyl-L-selenocysteine Chemical compound C[Se]C[C@H]([NH3+])C([O-])=O XDSSPSLGNGIIHP-VKHMYHEASA-N 0.000 description 6
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 6
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 229960002718 selenomethionine Drugs 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229910052711 selenium Inorganic materials 0.000 description 5
- 229940091258 selenium supplement Drugs 0.000 description 5
- 125000002327 selenol group Chemical group [H][Se]* 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 4
- 241000269841 Thunnus albacares Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- -1 also called 3Clpro Proteins 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001125831 Istiophoridae Species 0.000 description 3
- 125000003130 L-selenocysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])[Se][H] 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- 241000269851 Sarda sarda Species 0.000 description 3
- 241000269821 Scombridae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- YWWZCHLUQSHMCL-UHFFFAOYSA-N diphenyl diselenide Chemical compound C=1C=CC=CC=1[Se][Se]C1=CC=CC=C1 YWWZCHLUQSHMCL-UHFFFAOYSA-N 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 235000020640 mackerel Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 2
- 101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001417523 Plesiopidae Species 0.000 description 2
- 241001396014 Priacanthus arenatus Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000269956 Thunnus maccoyii Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241001222097 Xenocypris argentea Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 150000003957 organoselenium compounds Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000028043 self proteolysis Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108010091324 3C proteases Proteins 0.000 description 1
- 101800001631 3C-like serine proteinase Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000131386 Aspergillus sojae Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101100338269 Caenorhabditis elegans his-41 gene Proteins 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000126495 Gymnosarda unicolor Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 101710144121 Non-structural protein 5 Proteins 0.000 description 1
- 101800000508 Non-structural protein 5 Proteins 0.000 description 1
- 101800002227 Papain-like protease nsp3 Proteins 0.000 description 1
- 101800001074 Papain-like proteinase Proteins 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 241000819847 Pomella Species 0.000 description 1
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 1
- 108700038444 SARS-CoV-2 papain-like protease Proteins 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000630524 Taractes rubescens Species 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 241000269957 Thunnus obesus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 229940065287 selenium compound Drugs 0.000 description 1
- 150000003343 selenium compounds Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AVYHJCYFUREZKB-UHFFFAOYSA-M sodium hydrogen selenite selenous acid Chemical compound [Na+].O[Se](O)=O.O[Se]([O-])=O AVYHJCYFUREZKB-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
Definitions
- the present invention relates to the technical field of COVID19 treatment or prevention, including selenoneine.
- Non-Patent Document 1 Am J Clin Nutr. 2020 Jun 1;111(6):1297-1299. doi : 10.1093/ajcn/nqaa095).
- Coronaviruses have single-stranded RNA as their genome, and when they infect host cells, long polyproteins are translated from the RNA genome. Proper cleavage of the polyprotein allows each fragment to function as a structural protein or enzyme necessary for viral replication, resulting in viral replication.
- Proteases that mainly catalyze polyprotein cleavage include the main protease (M pro ) and papain-like protease (PLpro), and these proteases are potential drug discovery targets. Results of computer screening of three-dimensional models by crystallography have reported that some existing drugs can function as effective M pro inhibitors (Non-Patent Document 2: Nature (2020) vol. 582(7811):289-293).
- Ebselen which is a type of selenium compound, shows a remarkable affinity for the catalytic domain, and is expected to be developed as a therapeutic agent for COVID19 (Non-Patent Document 3: Sci. Adv. 2020 6 eadb0345).
- Ebselen is a functional molecule containing selenium, one of the essential trace elements, in its molecule.
- Ebselen is a molecule that potentially has a free selenol group as a tautomer.
- the mechanism of M pro inhibition by ebselen is thought to be covalent bonding of the selenol group of ebselen to the Cys145 thiol group of the active center of the protease.
- organoselenium compounds show high binding affinity to the main protease (M pro ) of SARS-CoV-2, suggesting that organoselenium compounds can be candidate molecules for antiviral drugs.
- M pro main protease
- the purpose is to provide a drug that has inhibitory activity against the protease of SARS-CoV-2, which is a target for drug discovery.
- the present inventors focused on the fact that both the main protease (M pro ) and papain-like protease (PLpro) of SARS-CoV-2 are cysteine proteases, and established a screening system using papain inhibitory activity as an indicator. Using such a screener, selenoneine was screened as a substance having a higher inhibitory activity than ebselen, which was identified as an inhibitor of Mpro . Furthermore, they prepared M pro of SARS-CoV-2 and confirmed that protease activity is inhibited by selenoneine, leading to the present invention.
- the invention thus relates to:
- a coronavirus protease inhibitor comprising selenoneine or a tautomer or dimer thereof or a pharmaceutically acceptable salt thereof.
- the protease inhibitor according to item 1 wherein the protease is main protease or papain-like protease.
- the protease inhibitor according to item 1, wherein the coronavirus is SARS-CoV2.
- a composition for treating or preventing coronavirus infection comprising selenoneine, a tautomer or dimer thereof, or a pharmaceutically acceptable salt thereof.
- Selenoneine or a tautomer or dimer thereof or a pharmaceutically acceptable salt thereof for use in treating or preventing coronavirus infection.
- the invention according to any one of items [4-1] to [4-4], wherein the coronavirus infection is COVID19.
- [6] A method for screening therapeutic or preventive agents for coronavirus infections, using inhibitory activity against papain as an index.
- the method according to item 6, wherein the coronavirus infection is COVID19.
- the therapeutic or prophylactic agent inhibits main protease or papain-like protease of coronavirus.
- Selenoneine exerts higher M pro inhibitory activity than ebselen. In addition, selenoneine exhibits higher M pro inhibitory activity than other selenium-containing compounds.
- FIG. 1 is a three-dimensional model showing that ebselen acts on the active center of M pro .
- the selenol group which appeared by tautomerization of ebselen, covalently bonds to cysteine 145.
- FIG. 2 shows a comparison of the sequence and active center conformation of (1) M pro , which is a cysteine protease, and (2) papain sequence and conformation of the active center.
- FIG. 3 shows a comparison of the sequence and active center conformation of (1) PLpro, a cysteine protease, and (2) papain sequence and conformation of the active center.
- Figure 4 shows papain enzymatic activity in the presence or absence of ebselen or selenoneine.
- FIG. 5 shows inhibition curves of ebselen or selenoneine on papain enzymatic activity.
- FIG. 6 shows a schematic diagram of a plasmid carrying the M pro gene.
- FIG. 7 shows the results of SDS-PAGE of M pro expressed in E. coli and purified with a His tag. The 33.8 kDa band corresponds to the Mpro band.
- Figure 8 shows the protease activity of Mpro in the presence or absence of ebselen, ergothioneine or selenoneine. M pro decomposes the fluorescent substrate, resulting in an increase in fluorescence intensity over time.
- FIG. 5 shows inhibition curves of ebselen or selenoneine on papain enzymatic activity.
- FIG. 6 shows a schematic diagram of a plasmid carrying the M pro gene.
- FIG. 7 shows the results of SDS-PAGE of M pro expressed in E. coli and purified with a His tag. The 33.8
- FIG. 10 shows test compounds (selenoine, ebselen , selenocystine ((SeCys) 2 ), methylselenocysteine (MeSeCys), selenomethionine (SeMet), diphenyldiselenide (PhSeSePh), sodium selenite ( selenite)).
- this embodiment an embodiment of the present invention (hereinafter referred to as “this embodiment”) will be described in detail, but the present invention is not limited to this, and various modifications are possible without departing from the scope of the invention. is.
- the present invention relates to a coronavirus protease inhibitor or a composition for the treatment or prevention of coronavirus infection, containing selenoneine or a tautomer or dimer thereof, or a pharmaceutically acceptable salt thereof.
- selenoneine has the following chemical name: 2-selenyl-N ⁇ ,N ⁇ ,N ⁇ -trimethyl - L - histidine is a compound of Specifically, the following formula (I): refers to a compound represented by The OH group, NH group, etc. in the molecule may be in a state without hydrogen atoms, that is, in an ionized state. This compound may exist as any optical isomer, geometric isomer, tautomer, or dimer, or mixtures thereof.
- selenoneine may take any of the forms of formulas (I)-(III) below:
- selenoneine may contain compounds in the form of formulas (I)-(III) in any proportion.
- a dimerized compound can be reduced to a monomer by the ambient environment.
- the composition containing the compound of formula (I) or (II) may further contain a reducing agent.
- Any reducing agent can be used as such a reducing agent, and examples thereof include glutathione (GSH), dithiothreitol (DTT), and mercaptoethanol.
- Selenoneine is a component that is abundantly contained in blood such as tuna, marlin, and mackerel, and is a component that is ingested on a daily basis.
- Selenoneine can be produced as appropriate by those skilled in the art.
- a method for producing selenoneine it can be produced by a chemical synthesis method (Angew. Chem. Int. Ed. 2019, 58, 1-6), or by extraction from a biological tissue containing selenoneine, or by fermentation with microorganisms. can be manufactured.
- ergothioneine is produced simultaneously with selenoneine, and it is difficult to separate them.
- the resulting transformant extract containing selenoneine may contain ergothioneine in addition to selenoneine.
- the selenoneine is preferably purified selenoneine.
- Selenoneine can be purified by techniques known to those skilled in the art, such as HPLC.
- coronavirus protease preferably relates to the SARS-CoV2 protease.
- Coronavirus proteases include the main protease ( Mpro ) and the papain-like protease (PLpro).
- Mpro main protease
- PLpro papain-like protease
- SARS-CoV2 main protease (M pro ) is preferred from the viewpoint of drug discovery targets.
- the main protease also called 3Clpro, nonstructural protein 5 (nsp5), relates to the main protease that degrades polyproteins.
- the main protease is a cysteine protease and functions as a dimer composed of identical subunits.
- the main protease of SARS-CoV2 has an amino acid sequence (SEQ ID NO: 1) consisting of 306 residues. An active center formed from such sequence Cys145 and His41 is known, and the selenol group of ebselen is believed to covalently bond to the thiol group of Cys145 (Fig. 1).
- Selenoneine which is a selenium-containing compound, also has a selenol group, so that it can covalently bind to Cys145 of the active center of M pro and have M pro inhibitory activity.
- Papain-like proteases are related to nonstructural protein 3 (nsp3) proteases and are cysteine proteases that degrade polyproteins.
- the papain-like protease of SARS-CoV2 has an amino acid sequence (SEQ ID NO: 3) consisting of 317 residues.
- the catalytic triad structure spanning the active center of papain-like protease is Asp286-His272-Cys111.
- Papain is a type of cysteine protease contained in papaya and has an amino acid sequence (SEQ ID NO: 2) consisting of 345 residues.
- a cysteine protease refers to a proteolytic enzyme that contains a cysteine in the catalytic domain of the enzyme. Cysteine thiols are deprotonated by histidines, which are normally located near cysteines in the catalytic domain, and the anionized thiol groups attack the carbonyl carbons of substrate peptides or proteins, hydrolyzing peptide bonds. Therefore, covalent binding of a protease inhibitor to the thiol groups of cysteines in the catalytic domain inhibits the enzymatic activity of cysteine proteases.
- Both papain and the main protease or papain-like protease are cysteine proteases, and form catalytic triads or catalytic dyads characterized by amino acid residues common to the active centers.
- Catalytic triad refers to the three coordinating amino acids found in the active site of some enzymes. The constituent coordinating amino acids differ depending on the type of enzyme.
- Catalytic triads of cysteine proteases are composed of cysteine, histidine, and asparagine or aspartic acid as the third amino acid.
- Such a screening method specifically includes preparing a solution containing a candidate agent, a papain-degrading fluorescent substrate, and papain, and measuring the fluorescence intensity of the solution.
- the fluorescence intensity over time may be measured, or the papain inhibition curve of the candidate drug may be obtained by measuring the change in fluorescence intensity when the concentration of the candidate drug is changed.
- selenonein that exhibits papain inhibitory activity may have inhibitory activity on the main protease or papain-like protease.
- the protease inhibitor of the present invention can suppress the proliferation of coronaviruses by suppressing the degradation of polyproteins produced from coronaviruses, and can thereby be used as therapeutic and prophylactic agents. Also, the protease inhibitors of the present invention may be included in foods or food compositions.
- composition of the present invention comprises a therapeutically effective amount of selenoneine or a tautomer or dimer thereof or a pharmaceutically acceptable salt thereof. Additionally, a pharmaceutically acceptable carrier or excipient may be included. Therefore, the composition of the present invention can also be called a pharmaceutical composition.
- the protease inhibitors and compositions of the invention are administered to patients in need of treatment or prevention.
- Another aspect of the present invention is the use of selenoneine or a tautomer or dimer thereof or a pharmaceutically acceptable salt thereof, a protease inhibitor according to the present invention, or a therapeutic or prophylactic pharmaceutical composition for treatment or prevention.
- the dosage/number of doses can be appropriately selected depending on the symptoms.
- pharmaceutically acceptable excipient includes any carrier, diluent, adjuvant or medium, preservative or antioxidant, filler, disintegrant, wetting agent, emulsifier, suspending agent. Also included are clouding agents, solvents, dispersion media, coatings, antibacterial agents, fungicides, isotonic agents and absorption retardants and the like.
- clouding agents solvents, dispersion media, coatings, antibacterial agents, fungicides, isotonic agents and absorption retardants and the like.
- Excipients can be used in the compositions of the present invention, except where conventional excipients are incompatible with selenoneine. Supplementary active ingredients can also be incorporated into the compositions as appropriate therapeutic combinations.
- Subjects who need treatment or prevention include those who may be exposed to coronavirus.
- a “therapeutically effective amount” is an amount that, when administered, is capable of inhibiting active proteases involved in pathogenesis, and which, when administered, is effective in preventing or treating the onset or exacerbation of COVID 19.
- a therapeutically effective amount can be determined through animal experiments and human clinical trials.
- selenoneine which is an active ingredient of the present invention, is ingested by eating fish. can also be used to determine the therapeutically effective amount.
- selenoneine can be administered at 28 ⁇ g/kg, but is not intended to be limited to these amounts.
- compositions of the present invention can be provided in any dosage form, including tablets, capsules, powders, nasal drops, or aerosol forms, injection solutions, drops, ointments, creams, sprays, transdermal patches. can be formulated into
- Another aspect of the invention may relate to a food composition
- a food composition comprising selenoneine or a tautomer or dimer thereof or a food acceptable salt thereof.
- Such food compositions include functionally labeled foods, nutritionally functional foods, and functionally labeled foods that display functions such as prevention and resistance to coronaviruses, particularly SARS-CoV2, or functions to inhibit coronavirus protease, particularly the main protease. Or it may be a food for specified health use.
- a food composition, a food with function claims, a food with nutrient function claims, or a food for specified health uses for example, contains 1 to 1000 ppm, preferably 10 to 100 ppm, and most preferably 30 to 70 ppm of selenoneine or a tautomer or dimeric form thereof. It may be a beverage, food, or supplement containing the polymer or its food-acceptable salt. Selenoneine is known to be abundant in fish.
- the selenoneine content in bluefin tuna is 30 mg Se/kg, and that 100 g of fish meat is eaten and uniformly distributed in a human body weighing 60 kg, the selenoneine content in the body is theoretically about 1 ⁇ M, and the blood concentration is It can be estimated to be approximately 8 ⁇ M.
- Fish that may contain selenoneine include tuna, marlin, mackerel, yellowtail, sea bream, pufferfish, salmon/trout, flounder/flatfish, and particularly tuna, marlin, mackerel, A lot of yellowtails are included.
- Examples of food compositions, foods with function claims, foods with nutrient function claims, or foods for specified health uses include raw edible parts of these fish and processed foods made from fish. These fish may be wild or farmed. Since the selenoneine content in fish varies depending on the type of feed, farmed fish with increased selenonein content are more preferred.
- Examples of processed foods made from fish include any foods made from fish, such as canned food, bottled food, food boiled in soy sauce, dried fish, dried fish, paste, pickled fish, and supplements.
- Tuna species used in food compositions, foods with function claims, foods with nutrient function claims, or foods for specified health uses include the tuna family and the Hagatsuo family.
- Examples of the tuna family include the genus Tuna, the genus Pomella, the genus Suma, and the genus Bonito, and examples of the genus Hagatsuo include the genus Dogtooth tuna and the genus Pomfret.
- tuna examples include albacore tuna, bluefin tuna, southern bluefin tuna, Atlantic tuna, Atlantic bluefin tuna, yellowfin tuna, bigeye tuna, and the like; Alternatively, mention may be made of albacore, bluefin tuna, southern bluefin tuna, Atlantic tuna, Atlantic bluefin tuna, yellowfin, bigeye, longfin, bonito or trout. Preferable examples include albacore, bluefin tuna, Atlantic bluefin tuna, bluefin tuna, yellowfin, bigeye, longfin, bonito, and trout.
- Example 1 Inhibitory Activity of Papain Activity 10 ⁇ g/ml of papain (sold by Sigma-Aldrich Japan) and 5 ⁇ M of ebselen or selenoneine were dissolved in 50 mM Tris-HCl (pH 7.4) kept at 37° C., After preincubation for 15 minutes, 10 ⁇ M Bz-Arg-MCA was added to the same reaction solution, and changes in fluorescence intensity due to cleavage of Bz-Arg-MCA were observed over time with a fluorometer. The results are shown in FIG.
- Example 2 Preparation of M pro of SARS-CoV2 M pro DNA was synthesized according to the nucleotide sequence of NC_45512 (10055-10972: SEQ ID NO: 4) by total gene synthesis.
- Mpro was introduced into a GST- and histidine-tagged plasmid (Fig. 6) and transformed into E. coli strain BL21(DE3).
- E. coli BL21(DE3) strain was cultured at 37° C. to express the M pro protein.
- Cell bodies were harvested and the M pro protein was purified using a binding agent for histidine tags.
- M pro and human rhinovirus 3C protease HRV
- HRV human rhinovirus 3C protease
- a binding agent for histidine tag was used to remove undigested M pro and HRV to obtain a purified preparation of M pro protein.
- Purified M pro protein was dissolved in a storage buffer of 20 mM Tris-HCl, 100 mM NaCl, 0.01% Triton-X-100, 50% glycerol, 1 mM EDTA, 1 mM DTT, subjected to SDS-PAGE and analyzed with Coomassie brilliant. Stained with blue (Fig. 7).
- the purified M pro protein dissolved in a storage buffer containing DTT was dialyzed using a microdialysis cartridge Xpress Micro / Mini Dialyzer (manufactured by Funakoshi Co., Ltd.) to remove DTT and inhibit the inhibitory activity of Example 4. submitted for testing.
- Example 3 Preparation of PLpro of SARS-CoV2 PLpro DNA is synthesized according to the base sequence of SEQ ID NO: NC_45512 (4955-5908: SEQ ID NO: 5) by total gene synthesis.
- PLpro is introduced into a histidine-tagged plasmid and transformed into E. coli strain BL21(DE3).
- E. coli strain BL21(DE3) is cultured to express the PLpro protein.
- Cell bodies are harvested and the PLpro protein purified using a binding agent to the histidine tag. GST and histidine tag are removed by autolysis of PLpro and HRV, and a binder for histidine tag is used to remove undigested PLpro and HRV to obtain a purified product of PLpro protein.
- Example 4 SARS-CoV2 inhibitory activity against M pro 2 ⁇ g/ml of M pro and 5 ⁇ M of ebselen, selenoneine, or ergothioneine were each dissolved in 50 mM Tris-HCl (pH 7.4) kept at 37°C. , After preincubation for 5 minutes, 10 ⁇ M Ac-Abu-Tle-Leu-Gln-MCA was added to the same reaction solution, and Ac-Abu-Tle-Leu-Gln-MCA was cleaved with a fluorometer. Inhibitory activity was examined by measuring changes in fluorescence intensity (Fig. 8).
- Example 5 SARS-CoV2 inhibitory activity against M pro 2 ⁇ g/ml of M pro and 1 ⁇ M of test compound were each dissolved in 50 mM Tris-HCl (pH 7.4) kept at 37° C. and preincubated. After 5 minutes, 10 ⁇ M Ac-Abu-Tle-Leu-Gln-MCA was added to the same reaction solution, and the fluorescence intensity accompanying the cleavage of Ac-Abu-Tle-Leu-Gln-MCA was measured with a fluorometer. to measure the inhibitory activity (Fig. 10).
- Selenoneine was about 20%, while ebselen, selenocystine ((SeCys) 2 ), methyl Selenocysteine (MeSeCys), selenomethionine (SeMet), diphenyldiselenide (PhSeSePh) and sodium selenite (selenite) were all above 90%. Therefore, it was shown that selenoneine is remarkably superior to other selenium-containing compounds, particularly in terms of M pro inhibitory activity.
- Example 6 Growth Inhibitory Activity against SARS-CoV2 Inhibition of SARS-CoV2 infection of host cells by ebselen or selenoneine can be measured, for example, by plaque assay.
- Host cells are grown in monolayers in a 37° C., 5% CO 2 incubator until confluent. Next, after removing the medium and washing the cell surface with PBS(-), a virus solution and a 0 to 100 ⁇ M protease inhibitor solution are added and incubated for 30 minutes. After 30 minutes, the sample solution is removed and an agar medium is overlaid. When the agar has hardened, the plates are inverted and incubated in a 37°C, 5% CO2 incubator for 2 days.
- the layered medium is removed, the plate is dried, stained with a crystal violet staining solution for 5 minutes, washed with purified water, and air-dried. Finally, the number of plaques is counted, compared with the control group, and the infection inhibition rate of the protease inhibitor against the virus is calculated.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
[2] 前記プロテアーゼが、メインプロテアーゼ又はパパイン様プロテアーゼである、項目1に記載のプロテアーゼ阻害剤。
[3] 前記コロナウイルスが、SARS-CoV2である、項目1に記載のプロテアーゼ阻害剤。
[4-1] セレノネイン又はその互変異性体若しくは二量体或いはその医薬として許容される塩を含む、コロナウイルス感染症の治療又は予防用の組成物。
[4-2] コロナウイルス感染症の治療又は予防において使用するためのセレノネイン又はその互変異性体若しくは二量体或いはその医薬として許容される塩。
[4-3] コロナウイルスによる感染の治療又は予防を必要とする対象における、コロナウイルス感染症を治療又は予防するための方法であって、前記対象に対して、セレノネイン又はその互変異性体若しくは二量体或いはその医薬として許容される塩を投与することを含む、前記方法。
[4-4] コロナウイルスの治療薬又は予防薬の製造のための、セレノネイン又はその互変異性体若しくは二量体或いはその医薬として許容される塩の使用。
[5] 前記コロナウイルス感染症が、COVID19である、項目[4-1]~[4-4]のいずれか一項に記載の発明。
[7] 前記コロナウイルス感染症が、COVID19である、項目6に記載の方法。
[8] 前記治療薬又は予防薬が、コロナウイルスのメインプロテアーゼ又はパパイン様プロテアーゼを阻害する、項目6又は7に記載の方法。
セレノネインが含まれうる魚類としては、マグロ類、カジキ類、サバ類、ブリ類、タイ類、フグ類、サケ・マス類、ヒラメ・カレイ類が挙げられ、特にマグロ類、カジキ類、サバ類、ブリ類に多く含まれる。食品組成物、機能性表示食品、栄養機能食品、又は特定保健用食品として、これらの魚類の生食可食部、又は魚類を原料とする加工食品が挙げられる。これらの魚類は天然物又は養殖物であってもよい。魚類中のセレノネイン含量は、餌の種類によって変動するため、より好ましくは、セレノネイン含量が増加された養殖魚が好ましい。魚類を原料とする加工食品としては、缶詰、瓶詰、佃煮、乾燥魚、干物、練り物、漬け魚、サプリメントなど、魚を原料とする任意の食品が挙げられる。
10μg/mlのパパイン(販売元:シグマアルドリッチジャパン)と、5μMのエブセレン又はセレノネインを、37℃に保った50mMのTris-HCl(pH7.4)に溶解し、プレインキュベーションを15分間行った後に、同反応液に10μMのBz-Arg-MCAを添加し、蛍光光度計でBz-Arg-MCAの切断に伴う蛍光強度変化を時間を追って観察した。結果を図4に示す。
遺伝子全合成により、NC_45512の塩基配列(10055-10972:配列番号4)に従ってMproのDNAを合成した。MproをGSTおよびヒスチジンタグ付きのプラスミドに導入し(図6)、大腸菌BL21(DE3)株にトランスフォーメーションした。大腸菌BL21(DE3)株を、37℃で培養し、Mproタンパク質を発現させた。細胞体を回収し、ヒスチジンタグに対する結合剤を用いて、Mproタンパク質を精製した。Mproの自己消化とヒトライノウイルス3Cプロテアーゼ(HRV)によってGSTとヒスチジンタグを除去し、ヒスチジンタグに対する結合剤を用いて、未消化のMproとHRVを除去し、Mproタンパク質の精製標品を得た。精製したMproタンパク質を、20mM Tris-HCl、100mM NaCl、0.01%Triton-X-100、50%グリセロール、1mM EDTA、1mM DTTの貯蔵緩衝液に溶解し、SDS-PAGEに供し、クマシーブリリアントブルーにより染色した(図7)。DTTを含有する貯蔵緩衝液に溶解した精製Mproタンパク質を、微量透析カートリッジXpress Micro / Mini Dialyzer(販売元:フナコシ株式会社)を用いて透析することでDTTを除去し、実施例4の阻害活性試験に供した。
遺伝子全合成により、配列番号NC_45512の塩基配列(4955-5908:配列番号5)に従ってPLproのDNAを合成する。PLproをヒスチジンタグ付きのプラスミドに導入し、大腸菌BL21(DE3)株にトランスフォーメーションする。大腸菌BL21(DE3)株を培養し、PLproタンパク質を発現せる。細胞体を回収し、ヒスチジンタグに対する結合剤を用いて、PLproタンパク質を精製する。PLproの自己消化とHRVによってGSTとヒスチジンタグを除去し、ヒスチジンタグに対する結合剤を用いて、未消化のPLproとHRVを除去し、PLproタンパク質の精製標品を得る。
2μg/mlのMproと、5μMのエブセレン、セレノネイン、又はエルゴチオネインをそれぞれ、37℃に保った50mMのTris-HCl(pH7.4)に溶解し、プレインキュベーションを5分間行った後に、同反応液に10μMのAc-Abu-Tle-Leu-Gln-MCAを添加し、蛍光光度計でAc-Abu-Tle-Leu-Gln-MCAの切断に伴う蛍光強度変化を測定して阻害活性を調べた(図8)。対照として、阻害化合物未添加の点でのみ異なる条件で蛍光強度変化を測定した。
Ac-Abu-Tle-Leu-Gln-MCAは、Mproにより分解され下記の通り、蛍光物質を生成し、Mpro阻害化合物の作用により蛍光物質の生成が抑制される。
2μg/mlのMproと、1μMの試験化合物をそれぞれ、37℃に保った50mMのTris-HCl(pH7.4)に溶解し、プレインキュベーションを5分間行った後に、同反応液に10μMのAc-Abu-Tle-Leu-Gln-MCAを添加し、蛍光光度計でAc-Abu-Tle-Leu-Gln-MCAの切断に伴う蛍光強度を測定して、阻害活性を測定した(図10)。試験化合物としては、セレノネイン、エブセレン、セレノシスチン((SeCys)2)、メチルセレノシステイン(MeSeCys)、セレノメチオニン(SeMet)、ジフェニルジセレニド(PhSeSePh)、亜セレン酸ナトリウム(sodium selenite)を用いた。亜セレン酸ナトリウムを除くこれらの含セリン化合物は、インシリコの試験において、Mpro阻害活性を有すると予測された化合物である(非特許文献4)。試験化合物未添加の蛍光強度を100とした場合の、試験化合物添加1分後の蛍光強度を測定したところ、セレノネインは約20%であった一方、エブセレン、セレノシスチン((SeCys)2)、メチルセレノシステイン(MeSeCys)、セレノメチオニン(SeMet)、ジフェニルジセレニド(PhSeSePh)、亜セレン酸ナトリウム(selenite)はいずれも90%超であった。したがって、セレノネインが、他の含セレン化合物と比較して、特にMpro阻害活性の点で顕著に優れていることが示された。
エブセレン又はセレノネインによるSARS-CoV2の宿主細胞への感染阻害は、例えば、プラークアッセイ法によって測定することができる。宿主細胞を37℃、5%CO2のインキュベーターでコンフルエントになるまで単層培養する。次に培地を除去し、PBS(-)にて細胞表面を洗浄した後、ウイルス溶液と、0から100μMのプロテアーゼ阻害剤溶液を添加し30分間インキュベーションを行う。30分後に検体溶液を除去し、寒天培地を重層する。寒天が固まったらプレートを反転し37℃、5% CO2のインキュベーターで2日間インキュベートする。その後重層培地を外し、プレートを乾燥させ、クリスタルバイオレット染色液にて5分間染色を行った後、精製水で洗浄し風乾させる。最後にプラークの数をカウントし、対照群と比較し、ウイルスに対するプロテアーゼ阻害剤の感染阻害率を計算する。
Claims (9)
- セレノネイン、又はその互変異性体若しくは二量体、或いはその医薬として許容される塩を含む、コロナウイルスのプロテアーゼ阻害剤。
- 前記プロテアーゼが、メインプロテアーゼ又はパパイン様プロテアーゼである、請求項1に記載のプロテアーゼ阻害剤。
- 前記コロナウイルスが、SARS-CoV2である、請求項1又は2に記載のプロテアーゼ阻害剤。
- セレノネイン又はその互変異性体若しくは二量体或いはその医薬として許容される塩を含む、コロナウイルス感染症の治療又は予防用の組成物。
- 前記コロナウイルス感染症が、COVID19である、請求項4に記載の組成物。
- 請求項1~3のいずれか一項に記載のプロテアーゼ阻害剤を含む、コロナウイルス感染症の治療又は予防用の組成物。
- パパインに対しての阻害活性を指標とした、コロナウイルス感染症の治療又は予防薬のスクリーニング方法。
- 前記コロナウイルス感染症が、COVID19である、請求項7に記載の方法。
- 前記治療薬又は予防薬が、コロナウイルスのメインプロテアーゼを阻害する、請求項7又は8に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023500976A JPWO2022177029A1 (ja) | 2021-02-22 | 2022-02-22 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-026585 | 2021-02-22 | ||
JP2021026585 | 2021-02-22 | ||
JP2021106076 | 2021-06-25 | ||
JP2021-106076 | 2021-06-25 | ||
JP2021-165803 | 2021-10-07 | ||
JP2021165803 | 2021-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022177029A1 true WO2022177029A1 (ja) | 2022-08-25 |
Family
ID=82931986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/007397 WO2022177029A1 (ja) | 2021-02-22 | 2022-02-22 | セレノネインを含む、covid19治療又は予防薬 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2022177029A1 (ja) |
TW (1) | TW202302093A (ja) |
WO (1) | WO2022177029A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737675A (zh) * | 2022-11-28 | 2023-03-07 | 安徽农业大学 | 氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用 |
-
2022
- 2022-02-22 JP JP2023500976A patent/JPWO2022177029A1/ja active Pending
- 2022-02-22 TW TW111106368A patent/TW202302093A/zh unknown
- 2022-02-22 WO PCT/JP2022/007397 patent/WO2022177029A1/ja active Application Filing
Non-Patent Citations (4)
Title |
---|
CHEN, L.R. WANG, Y.C. LIN, Y.W. CHOU, S.Y. CHEN, S.F. LIU, L.T. WU, Y.T. KUO, C.J. CHEN, T.S.S. JUANG, S.H.: "Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 15, no. 12, 15 June 2005 (2005-06-15), Amsterdam NL , pages 3058 - 3062, XP004915597, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2005.04.027 * |
JI-YOUNG PARK, JANG HOON KIM, YOUNG MIN KIM, HYUNG JAE JEONG, DAE WOOK KIM, KI HUN PARK, HYUNG-JUN KWON, SU-JIN PARK, WOO SONG LEE: "Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 19, 1 October 2012 (2012-10-01), AMSTERDAM, NL, pages 5928 - 5935, XP055567436, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2012.07.038 * |
SINGH BEENA GOBIND, KUNWAR AMIT: "In Silico Investigation on the Binding of Organoselenium Compounds with Target Proteins of SARS-CoV-2 Infection Cycle", CHEMRXIV, 2 July 2020 (2020-07-02), XP055960644, Retrieved from the Internet <URL:https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/60c74d2d842e656b13db33f1/original/in-silico-investigation-on-the-binding-of-organoselenium-compounds-with-target-proteins-of-sars-co-v-2-infection-cycle.pdf> [retrieved on 20220913], DOI: 10.26434/chemrxiv.12594134.v1 * |
YAMASHITA, MICHIAKI: ""Selenium", which is abundant in fish, is also effective against new coronavirus", YOSHOKU BIJINESU = AQUA CULTURE BUSINESS, vol. 57, no. 10, 1 October 2020 (2020-10-01), pages 62 - 67, XP009539145, ISSN: 2187-1442 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737675A (zh) * | 2022-11-28 | 2023-03-07 | 安徽农业大学 | 氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用 |
CN115737675B (zh) * | 2022-11-28 | 2024-03-08 | 安徽农业大学 | 氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022177029A1 (ja) | 2022-08-25 |
TW202302093A (zh) | 2023-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Anirudhan et al. | Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19 | |
Bai et al. | Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors | |
JP5952967B2 (ja) | ジペプチジルペプチダーゼiv(dppiv)阻害ペプチド化合物、それを含有する組成物、及びその製造方法 | |
JP2009538881A (ja) | タンパク質フォールディング及びタンパク質分解の阻害による、ウィルス感染及び/又は腫瘍疾患の治療のための医薬組成物 | |
CN113289018A (zh) | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 | |
WO2022177029A1 (ja) | セレノネインを含む、covid19治療又は予防薬 | |
Kuo et al. | Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus | |
Tao et al. | Inhibition of SARS-CoV-2 replication by zinc gluconate in combination with hinokitiol | |
Shao et al. | Cytotoxicity induced by grape seed proanthocyanidins: role of nitric oxide | |
Wu et al. | Antiviral drug discovery against SARS-CoV | |
US20160000749A1 (en) | Method of Inhibiting or Treating a Dengue Virus Infection with Quercetin | |
Dinda et al. | Anti-SARS-CoV-2, antioxidant and immunomodulatory potential of dietary flavonol quercetin: Focus on molecular targets and clinical efficacy | |
JP5220415B2 (ja) | 老人性貧血を防止又は治療するためのアミノ酸組成物 | |
US20050037953A1 (en) | Inhibitors of plasmepsins | |
EP3960241A1 (en) | Therapeutic agent for flavivirus infection | |
US10683316B2 (en) | Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections | |
CN113262224A (zh) | 奈非那韦在制备防治新冠肺炎药物中的应用 | |
JP5113348B2 (ja) | ユビキチンリガーゼ阻害剤 | |
CN107406485A (zh) | 用于治疗癌症的肽 | |
CN106038695B (zh) | 鳄梨萃取物、鳄梨醇b及(2r,4r)-1,2,4-三羟基十七碳-16-炔的用途,以及包含鳄梨萃取物的保健食品 | |
US8741856B2 (en) | Avermectins and milbemycins for the treatment, prevention or amelioration of flavivirus infections | |
US11213511B2 (en) | Composition for preventing or treating SARS coronavirus 2 infection disease | |
CN112294793B (zh) | 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用 | |
EP3050871B1 (en) | Novel bis-amide derivative and use thereof | |
JP2023525855A (ja) | コロナウイルスによる疾患の治療及び/又は予防のための化合物及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22756346 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023500976 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202317055401 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22756346 Country of ref document: EP Kind code of ref document: A1 |